Key facts
- ExoLab Italia’s last known valuation is $2.1M (Dec 2021).
- It has raised $5.9M; the latest was Early Stage VC ($5.3M) in Dec 2024.
- Notable investors include CDP Venture Capital (Rome), Maia Ventures, Marzotto Venture Accelerator, Riello Investimenti SGR, Scientifica — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for ExoLab Italia
- ·The full record, as it builds
Funding rounds
No funding rounds for ExoLab Italia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ExoLab Italia
Operator of a biotechnological company intended to create useful products based on vegetable nanovesicles. The company has its laboratory for research, innovation, and production of plant exosome extract from Italian organic agriculture, produces food supplements and cosmetics based on plant exosomes, and specializes in tailor-made consulting services, enabling clients to build research projects that meet their specific needs, up to the development of the formulations of finished products and accompanied by scientific dossiers.
- Sector
- Healthcare
- HQ
- L'Aquila, Italy
- Founded
- 2020
- Employees
- 10
- Website
- exolabitalia.net/
- Ownership
- Privately Held (backing)
ExoLab Italia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ExoLab Italia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ExoLab Italia in its N-PORT filings yet. We sweep new filings monthly.